MRNA · Healthcare · $75.1B
After-hours $189.30+0.19%
What's this stock's score right now?
See its score for free — revenue and money flow, graded on one standard.
Quarterly Financials
9/'26
6/'26 vs prev quarter
Short Float 8.8% · biweekly · settled 26.09.15
Among 327 Biotechnology peers
Quarterly Revenue Growth
“모더나의 가장 큰 기대주는 '인티스메란(Intismeran)'이라는 개인 맞춤형 암 치료 백신이에요.”
In the company's words · 2026 1분기 earnings call